1. Home
  2. MGNX vs VATE Comparison

MGNX vs VATE Comparison

Compare MGNX & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGNX
  • VATE
  • Stock Information
  • Founded
  • MGNX 2000
  • VATE 1994
  • Country
  • MGNX United States
  • VATE United States
  • Employees
  • MGNX N/A
  • VATE N/A
  • Industry
  • MGNX Biotechnology: Pharmaceutical Preparations
  • VATE Metal Fabrications
  • Sector
  • MGNX Health Care
  • VATE Industrials
  • Exchange
  • MGNX Nasdaq
  • VATE Nasdaq
  • Market Cap
  • MGNX 87.7M
  • VATE 98.2M
  • IPO Year
  • MGNX 2013
  • VATE 1996
  • Fundamental
  • Price
  • MGNX $1.33
  • VATE $5.26
  • Analyst Decision
  • MGNX Hold
  • VATE
  • Analyst Count
  • MGNX 9
  • VATE 0
  • Target Price
  • MGNX $5.33
  • VATE N/A
  • AVG Volume (30 Days)
  • MGNX 2.0M
  • VATE 44.2K
  • Earning Date
  • MGNX 08-05-2025
  • VATE 08-06-2025
  • Dividend Yield
  • MGNX N/A
  • VATE N/A
  • EPS Growth
  • MGNX N/A
  • VATE N/A
  • EPS
  • MGNX N/A
  • VATE N/A
  • Revenue
  • MGNX $154,050,000.00
  • VATE $1,066,100,000.00
  • Revenue This Year
  • MGNX N/A
  • VATE N/A
  • Revenue Next Year
  • MGNX N/A
  • VATE N/A
  • P/E Ratio
  • MGNX N/A
  • VATE N/A
  • Revenue Growth
  • MGNX 255.31
  • VATE N/A
  • 52 Week Low
  • MGNX $0.99
  • VATE $3.25
  • 52 Week High
  • MGNX $5.77
  • VATE $13.79
  • Technical
  • Relative Strength Index (RSI)
  • MGNX 41.45
  • VATE 39.84
  • Support Level
  • MGNX $1.33
  • VATE $5.17
  • Resistance Level
  • MGNX $2.17
  • VATE $5.55
  • Average True Range (ATR)
  • MGNX 0.17
  • VATE 0.28
  • MACD
  • MGNX -0.02
  • VATE -0.03
  • Stochastic Oscillator
  • MGNX 2.38
  • VATE 13.43

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.

Share on Social Networks: